KR960704568A - 이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해 항체 반응을 유도하는 방법(inducing antibody response against self-proteins with the aid of foreign t-cell epitores) - Google Patents
이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해 항체 반응을 유도하는 방법(inducing antibody response against self-proteins with the aid of foreign t-cell epitores)Info
- Publication number
- KR960704568A KR960704568A KR1019960701052A KR19960701052A KR960704568A KR 960704568 A KR960704568 A KR 960704568A KR 1019960701052 A KR1019960701052 A KR 1019960701052A KR 19960701052 A KR19960701052 A KR 19960701052A KR 960704568 A KR960704568 A KR 960704568A
- Authority
- KR
- South Korea
- Prior art keywords
- vaccine
- auto
- proteins
- treatment
- protein
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 6
- 230000005875 antibody response Effects 0.000 title claims 2
- 230000001939 inductive effect Effects 0.000 title claims 2
- 238000000034 method Methods 0.000 claims abstract description 5
- 229960005486 vaccine Drugs 0.000 claims abstract 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract 12
- 108090000623 proteins and genes Proteins 0.000 claims abstract 12
- 230000001105 regulatory effect Effects 0.000 claims abstract 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 2
- 241001465754 Metazoa Species 0.000 claims abstract 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract 2
- 201000011510 cancer Diseases 0.000 claims abstract 2
- 208000037976 chronic inflammation Diseases 0.000 claims abstract 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 229940079322 interferon Drugs 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010055044 Tetanus Toxin Proteins 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 229920002988 biodegradable polymer Polymers 0.000 claims 1
- 239000004621 biodegradable polymer Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 1
- 229930182490 saponin Natural products 0.000 claims 1
- 150000007949 saponins Chemical class 0.000 claims 1
- 229940118376 tetanus toxin Drugs 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
- 229940037642 autologous vaccine Drugs 0.000 abstract 2
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 102000044159 Ubiquitin Human genes 0.000 description 3
- 108010019759 OVA 323-339 Proteins 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 101500025132 Bos taurus Ubiquitin Proteins 0.000 description 1
- 101500027500 Bos taurus Ubiquitin Proteins 0.000 description 1
- 101500027539 Bos taurus Ubiquitin Proteins 0.000 description 1
- 101500028979 Bos taurus Ubiquitin Proteins 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- GSSMIHQEWAQUPM-AOLPDKKJSA-N ovalbumin peptide Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CN=CN1 GSSMIHQEWAQUPM-AOLPDKKJSA-N 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/77—Ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 하나 이상의 이종 T 세포 에피토우프를 분자 생물학적 수단에 의해 자가 단백질에 삽입시켜서 이러한 단백질을 면역원성으로 만드는 것으로 이루어지는, 자가 단백질을 제거 및/또는 조절하기 위한 면역장치를 이용하기 위한 방법에 관한 것이다. 조절된 단백질은 사람 또는 동물에게서 바람직하지 않은 단백질에 대한 자가 백신으로 사용될 수 있으며, 상기 자가 백신은 많은 질환, 예를 들어 암, 만성 염증성 질환, 류머티스 관절염, 염증성 장질환, 알레르기성 증상 또는 당뇨병에 대한 백신으로서 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 삽입된 이종 T 세포(MP7)를 사용하는 우비퀴틴 유전자의 구성에서 사용되는 클로닝 방법의 개략도이다,
제2도는 우비퀴틴, 및 삽입된 T 세포 에피토우프 OVA(323-339) 및 HEL(50-61)를 각각 함유하는 유사체로 면역시킨 마우스로부터의 혈청에서 면역된 소과 동물 우비퀴틴에 대한 반응성을 도시한 도면이다,
제2a도는 OVA(323-339)를 함유하는 재조합 오비퀴틴으로 면역시킨 Balb/c 마스크로부터의 혈청을 도시한 도면이다,
제2b도는 HEL(50-61)를 함유하는 재조합 우비퀴틴으로 면역시킨 Balb/c 마우스로부터의 혈청을 도시한 도면이다,
제2c도는 재조합 비-변형 우비퀴틴으로 면역시킨 Balb/c 마우스로부터의 혈청을 도시한 도면이다,
제3도는 재조합 TNF α 돌연변이의 구성에 사용되는 클리닝 방법의 개략도이다.
Claims (9)
- 하나 이상의 이종 T 세포 에피토우프를 분자 생물학적 수단에 의해 자가 단백질에 삽입시켜서 이러한 단백질을 면역원성으로 만드는 것을 특징으로 하는, 자가 단백질에 대한 항체 반응을 유도함으로써 자가 단백질을 조절하는 방법.
- 제1항에 있어서, 파상풍 독소 및 디프테리아 독소로부터의 면역 우세성 T 세포 에피토우프를 상기 단백질에 삽입시킴을 특징으로 하는 방법.
- 하나 이상의 제1항 또는 2항에 따라 조절된 단백질로 구성되고, 인산 칼슘, 사포닌, 퀼 A 및 생분해성 중합체와 같은 약제학적으로 허용될 수 있는 보조제에 의해 제형화되는 것을 특징으로 하는, 사람 또는 동물의 바람직하지 않은 단백질에 대한 자가 백신.
- 제3항에 있어서, 조절된 자가 단백질이 GM-CSH 또는 인터로이킨 2와 같은 적합한 면역 활성 세포질을 갖는 융합 단백질로서 제조됨을 특징으로 하는 자가 백신.
- 제3항에 있어서, 자가 백신이 악액질에 걸린 환자, 예를 들어 암환자의 치료를 위한, TNF α 또는 ｒ-인터페론에 대한 백신임을 특징으로 하는 자가 백신.
- 제3항에 있어서, 자가 백신이 알레르기성 질환에 걸린 환자의 치료를 위한, IgG에 대한 백신임을 특징으로 하는 자가 백신.
- 제3항에 있어서, 자가 백신이 만성 염증성 질환에 걸린 환자의 치료를 위한, TNF α, TNF β 및 인터페론1에 대한 백신임을 특징으로 하는 자가 백신.
- 제7항에 있어서, 자가 백신이 류머티스성 관절염 또는 염증성 장질환에 걸린 환자의 치료를 위한 백신임을 특징으로 하는 자가 백신.
- 제3항 또는 제4항에 있어서, 자가 백신이 당뇨병 치료를 위한, TNF α에 대한 백신임을 특징으로 하는 자가 백신.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK93964A DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| DK0964/93 | 1993-08-26 | ||
| PCT/DK1994/000318 WO1995005849A1 (en) | 1993-08-26 | 1994-08-25 | Inducing antibody response against self-proteins with the aid of foreign t-cell epitopes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR960704568A true KR960704568A (ko) | 1996-10-09 |
| KR100308444B1 KR100308444B1 (ko) | 2001-11-30 |
Family
ID=8099485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960701052A KR100308444B1 (ko) | 1993-08-26 | 1994-08-25 | 이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해항체반응을유도하는방법 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20020090379A1 (ko) |
| EP (1) | EP0752886B1 (ko) |
| JP (1) | JP3825041B2 (ko) |
| KR (1) | KR100308444B1 (ko) |
| AT (1) | ATE162723T1 (ko) |
| AU (1) | AU7608094A (ko) |
| CA (1) | CA2170236C (ko) |
| DE (1) | DE69408342T2 (ko) |
| DK (2) | DK96493D0 (ko) |
| ES (1) | ES2112559T3 (ko) |
| GR (1) | GR3026419T3 (ko) |
| WO (1) | WO1995005849A1 (ko) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410022B1 (en) | 1995-05-01 | 2002-06-25 | Avant Immunotherapeutics, Inc. | Modulation of cholesteryl ester transfer protein (CETP) activity |
| DK0831881T3 (da) | 1995-06-06 | 2003-07-07 | Avant Immunotherapeutics Inc | CETP til forøgelse af HDL-cholesterolniveau |
| WO1997021728A1 (en) | 1995-12-12 | 1997-06-19 | Karolinska Innovations Ab | PEPTIDE BINDING THE KLVFF-SEQUENCE OF AMYLOID $g(b) |
| AR012427A1 (es) * | 1997-04-15 | 2000-10-18 | Pharmexa As | Moleculas de ftn-alfa modificadas, adn codificada y vacunas que comprenden dicha modificacion ftn-alfa y adn |
| US6319503B1 (en) * | 1998-02-19 | 2001-11-20 | Proteinix Company | Heat shock fusion-based vaccine system |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6838269B1 (en) | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
| US6936249B1 (en) * | 1998-04-15 | 2005-08-30 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
| CN1318105A (zh) * | 1998-09-15 | 2001-10-17 | M&E生物技术公司 | 负调节Osteoprotegerin配体活性的方法 |
| DK1114166T3 (da) * | 1998-09-15 | 2005-08-01 | Pharmexa As | Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet |
| NZ511055A (en) | 1998-10-05 | 2003-10-31 | Pharmexa As | Novel methods for therapeutic vaccination |
| SI1117421T1 (en) * | 1998-10-05 | 2004-12-31 | Pharamexa A/S | Methods for therapeutic vaccination |
| DE69929232T2 (de) | 1998-10-21 | 2006-08-31 | The United States Government As Represented By The Department Of Health And Human Services | Virusähnliche partikel zur induktion von autoantikörpern |
| US6913749B2 (en) * | 1998-11-02 | 2005-07-05 | Resistentia Pharmaceuticals Ab | Immunogenic polypeptides for inducing anti-self IgE responses |
| EP1173573A1 (en) * | 1999-04-23 | 2002-01-23 | Pharmexa A/S | Method for down-regulating il5 activity |
| US7060670B1 (en) | 1999-05-05 | 2006-06-13 | Neurochem (International) Limited | Stereoselective antifibrillogenic peptides and peptidomimetics thereof |
| WO2000067777A1 (en) * | 1999-05-07 | 2000-11-16 | Biofan Pty Ltd | A method of prophylaxis and treatment and agents useful therefor |
| EE200200025A (et) * | 1999-07-20 | 2003-04-15 | Pharmexa A/S | Meetod GDF-8 aktiivsuse allareguleerimiseks, meetod looma lihasmassi suurendamiseks, GDF-8 analoog,immunogeenne kompositsioon, nukleiinhappefragment, vektor, transformeeritud rakk ja selle valmistamismeetod, kompositsioon GDF-8 vastaste antikehadeto |
| KR100879810B1 (ko) * | 2000-02-21 | 2009-01-22 | 하. 룬드벡 아크티에셀스카브 | 아밀로이드의 하향-조절을 위한 신규한 방법 |
| WO2001062284A2 (en) * | 2000-02-21 | 2001-08-30 | Pharmexa A/S | Novel method for down-regulation of amyloid |
| AU2001285721A1 (en) * | 2000-09-06 | 2002-03-22 | Pharmexa A/S | Method for down-regulating IgE |
| AU2002239410B2 (en) | 2000-10-31 | 2008-05-01 | Eisai Inc. | CYP1B1 nucleic acids and methods of use |
| US7097837B2 (en) | 2001-02-19 | 2006-08-29 | Pharmexa A/S | Synthetic vaccine agents |
| US20030166589A1 (en) * | 2001-06-05 | 2003-09-04 | Nathan Karin | Method and pharmaceutical composition for the treatment of multiple sclerosis |
| MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
| CN1615316A (zh) * | 2001-11-16 | 2005-05-11 | 法麦克萨有限公司 | 多聚体蛋白质的新免疫原性模拟物 |
| EP1485122A2 (en) * | 2002-03-11 | 2004-12-15 | Pharmexa A/S | Novel application of vaccination against tnf-alpha |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| ATE438857T1 (de) | 2002-06-13 | 2009-08-15 | Merck Patent Gmbh | Verfahren für die identifizierung von allo- antigenen und ihren verwendung für krebs therapie und transplantation |
| WO2004052930A2 (en) * | 2002-12-11 | 2004-06-24 | Pharmexa A/S | Targeting single epitopes |
| WO2005025613A1 (en) * | 2003-03-12 | 2005-03-24 | Rappaport Family Institute For Research In The Medical Sciences | Methods of identifying biomolecular targets for diagnosis and therapy |
| US8017113B2 (en) | 2003-03-12 | 2011-09-13 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating an inflammation |
| WO2004080273A2 (en) * | 2003-03-12 | 2004-09-23 | Rappaport Family Institute For Research In The Medical Sciences | Compositions and methods for diagnosing and treating prostate cancer |
| AU2004224093A1 (en) * | 2003-03-28 | 2004-10-07 | Innogenetics N.V. | Treatment of type 1 immune response-mediated inflammatory lung disease by modulation of IFN-gamma activity |
| KR20060033870A (ko) | 2003-06-25 | 2006-04-20 | 파멕사 에이/에스 | Ｈｅｒ-2 변이체의 정제 |
| JP4751984B2 (ja) * | 2004-09-27 | 2011-08-17 | 順 西平 | Ｄｎａワクチン |
| CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
| WO2007022813A2 (en) * | 2005-05-24 | 2007-03-01 | Neovacs | A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN |
| CA2628546A1 (en) * | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting hmgb1 |
| US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
| WO2007137586A2 (en) * | 2006-05-31 | 2007-12-06 | Pharmexa A/S | Random insertion of peptides |
| NZ575388A (en) | 2006-10-06 | 2012-03-30 | Bn Immunotherapeutics Inc | Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer |
| US8053231B2 (en) | 2007-04-03 | 2011-11-08 | Jun Nishihira | DNA vaccine |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| ES2498040T3 (es) | 2007-07-27 | 2014-09-24 | Janssen Alzheimer Immunotherapy | Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados |
| JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
| US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| SE535982C2 (sv) * | 2009-12-15 | 2013-03-19 | Theravac Pharmaceuticals Ab | Ett nytt vaccin som angriper tumörkärl som ett effektivt redskap i tumörterapi |
| CN105705522B (zh) * | 2013-05-14 | 2020-09-15 | 上海亨臻实业有限公司 | 针对低免疫原性蛋白的表位疫苗及其制法和用途 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES8407097A1 (es) * | 1982-05-12 | 1984-08-16 | Harvard College | Un procedimiento para obtener una proteina hibrida. |
| US4684623A (en) * | 1985-05-02 | 1987-08-04 | The Board Of Trustees Of The Cetus Corporation | Use of tumor necrosis factor as a weight regulator |
| US4772685A (en) * | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
| US5126399A (en) * | 1986-04-30 | 1992-06-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the preparation and use of site-directed immunologic reagents |
| EP0269455A3 (en) * | 1986-11-28 | 1989-09-06 | Takeda Chemical Industries, Ltd. | Highly purified fused protein comprising human ige fc fragment and production thereof |
| NL8700927A (nl) * | 1987-04-16 | 1988-11-16 | Stichting Rega V Z W | Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing. |
| GB8812214D0 (en) * | 1988-05-24 | 1988-06-29 | Hoffmann La Roche | Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope |
| DE68924850T2 (de) * | 1988-06-14 | 1996-10-10 | Cell Med Inc | Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren. |
| US5260422A (en) * | 1988-06-23 | 1993-11-09 | Anergen, Inc. | MHC conjugates useful in ameliorating autoimmunity |
| CA2047244C (en) * | 1989-02-24 | 2002-09-17 | Zanetti Maurizio | Genetically engineered immunoglobulins |
| GB8905400D0 (en) * | 1989-03-09 | 1989-04-19 | Jonker Margreet | Medicaments |
| WO1991001330A1 (en) * | 1989-07-14 | 1991-02-07 | Schering Corporation | Antagonists of gm-csf derived from the carboxyl terminus |
| IT1231727B (it) * | 1989-08-11 | 1991-12-21 | Enrico Savoldi | Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone. |
| US5969109A (en) * | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
| CH683101A5 (de) * | 1990-09-18 | 1994-01-14 | Biotech Australia Pty Ltd | T-Zellen-Epitope. |
| US5698195A (en) * | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| AU634379B2 (en) * | 1991-04-29 | 1993-02-18 | Csl Limited | Recombinant immunocastration vaccine |
| US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| SE9102808L (sv) * | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| AU4377793A (en) * | 1992-05-20 | 1993-12-13 | Johns Hopkins University, The | Alternative receptor therapy |
| US5716596A (en) * | 1992-06-23 | 1998-02-10 | Diatide, Inc. | Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses |
-
1993
- 1993-08-26 DK DK93964A patent/DK96493D0/da not_active Application Discontinuation
-
1994
- 1994-08-25 AU AU76080/94A patent/AU7608094A/en not_active Abandoned
- 1994-08-25 CA CA002170236A patent/CA2170236C/en not_active Expired - Lifetime
- 1994-08-25 AT AT94926106T patent/ATE162723T1/de not_active IP Right Cessation
- 1994-08-25 DE DE69408342T patent/DE69408342T2/de not_active Expired - Lifetime
- 1994-08-25 ES ES94926106T patent/ES2112559T3/es not_active Expired - Lifetime
- 1994-08-25 KR KR1019960701052A patent/KR100308444B1/ko not_active IP Right Cessation
- 1994-08-25 DK DK94926106.9T patent/DK0752886T3/da active
- 1994-08-25 WO PCT/DK1994/000318 patent/WO1995005849A1/en active IP Right Grant
- 1994-08-25 EP EP94926106A patent/EP0752886B1/en not_active Expired - Lifetime
- 1994-08-25 JP JP50727895A patent/JP3825041B2/ja not_active Expired - Fee Related
-
1997
- 1997-10-21 US US08/955,373 patent/US20020090379A1/en not_active Abandoned
-
1998
- 1998-03-20 GR GR980400609T patent/GR3026419T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0752886A1 (en) | 1997-01-15 |
| CA2170236C (en) | 2007-11-06 |
| WO1995005849A1 (en) | 1995-03-02 |
| US20020090379A1 (en) | 2002-07-11 |
| ES2112559T3 (es) | 1998-04-01 |
| KR100308444B1 (ko) | 2001-11-30 |
| DE69408342D1 (de) | 1998-03-05 |
| GR3026419T3 (en) | 1998-06-30 |
| DE69408342T2 (de) | 1998-05-14 |
| EP0752886B1 (en) | 1998-01-28 |
| ATE162723T1 (de) | 1998-02-15 |
| CA2170236A1 (en) | 1995-03-02 |
| JP3825041B2 (ja) | 2006-09-20 |
| DK0752886T3 (da) | 1998-05-04 |
| AU7608094A (en) | 1995-03-21 |
| DK96493D0 (da) | 1993-08-26 |
| JPH09505031A (ja) | 1997-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960704568A (ko) | 이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해 항체 반응을 유도하는 방법(inducing antibody response against self-proteins with the aid of foreign t-cell epitores) | |
| Good et al. | Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation of effect with biologic activity of IL-2. | |
| JP3583421B2 (ja) | ＩｇＥの不変部の一部を含有するＩｇＥ媒介アレルギー反応治療用ワクチン | |
| EP0271577B1 (en) | Immunomodulating compositions and their use | |
| KR937000141A (ko) | 비면역 유발성 운반체에 결합된 면역 유발원의 t세포 에피토프-결핍 유사물을 포함하며 면역유발원에 대한 체액성 아네르기를 유발하는 조성물 | |
| GB2251186A (en) | Polypeptide for use in treatment of autoimmune disease | |
| Sun et al. | Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice | |
| US6656462B2 (en) | Interleukin-1 muteins useful as vaccine adjuvants | |
| Sioud et al. | Characterization of naturally occurring autoantibodies against tumour necrosis factor‐alpha (TNF‐α): in vitro function and precise epitope mapping by phage epitope library | |
| WO2002053106A2 (en) | Autoantigen composition | |
| AU707083B2 (en) | Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes | |
| Castagliuolo et al. | Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant | |
| CA2286346A1 (en) | Peptides useful for reducing symptoms of toxic shock syndrome | |
| EP0841939A1 (en) | Therapeutic agents and autoimmune diseases | |
| Park et al. | Enhanced immune response with foot and mouth disease virus VP1 and interleukin-1 fusion genes | |
| IE911527A1 (en) | Improved vaccine compositions | |
| Pal et al. | Immunogenic and protective ability of the two developmental forms of Chlamydiae in a mouse model of infertility | |
| Kamada et al. | Preparation of a uveitogenic peptide by chymotryptic digestion of bovine S-antigen. | |
| Batteiger et al. | Immunization of guinea pigs with isolated chlamydial outer membrane proteins | |
| Silva et al. | Extract of Ascaris suum induces TGF-β and early production of IgG1 in experimental autoimmune hepatitis | |
| EP3400235A1 (en) | Method for treatment of self-protein-related diseases | |
| Birr | SYNTHETIC PEPTIDE VACCINES AND PROBLEMS ENCOUNTERED | |
| Schmucker | Efficacy of intraduodenal, oral and parenteral boosting in inducing intestinal mucosal immunity to cholera toxin in rats | |
| Pierre et al. | Mouse secretory component | |
| JPH10120591A (ja) | 免疫寛容誘導剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20080813 Year of fee payment: 8 |
|
| LAPS | Lapse due to unpaid annual fee |